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   Abstract  
Introduction: Non-vitamin K antagonist oral anticoagulants (NOACs), such as dabigatran and rivaroxaban, are now
available for stroke prevention in patients with atrial fibrillation (AF) and are often clinically preferred over vitamin K
antagonists (VKAs), such as warfarin. Data describing adherence and persistence to NOACs in real-life clinical practice
in Malaysia are scarce. This study aimed to assess adherence and persistence to NOACs in patients with AF in two
tertiary-care referral centers: Hospital Kuala Lumpur (HKL) and Hospital Serdang (HSDG). Materials and Methods:
This was a retrospective cohort study that included all patients with AF who were treated with NOACs (dabigatran or
rivaroxaban) in HKL and HSDG. Data were obtained from medical records and pharmacy databases. Adherence was
assessed using proportion of days covered (PDC) over a 1-year duration. High adherence was defined as PDC ≥80%. A
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Original Article
Assessing Adherence and Persistence to Non-vitamin K Antagonist Oral 
Anticoagulants (NOACs) among Patients with Atrial Fibrillation in 
Tertiary-care Referral Centers in Malaysia
Mohammed  A. Kubas1, Fatiha  Hana Shabaruddin2, Wardati Mazlan-Kepli3, Nirmala Jagan4, Sahimi Mohamed5, 
Nor Ilyani Mohamed Nazar1, Che Suraya Zin1
Introduction: Non-vitamin K antagonist oral anticoagulants (NOACs), such as 
dabigatran and rivaroxaban, are now available for stroke prevention in patients 
with atrial fibrillation (AF) and are often clinically preferred over vitamin 
K antagonists (VKAs), such as warfarin. Data describing adherence and 
persistence to NOACs in real-life clinical practice in Malaysia are scarce. This 
study aimed to assess adherence and persistence to NOACs in patients with AF in 
two tertiary-care referral centers: Hospital Kuala Lumpur (HKL) and Hospital 
Serdang (HSDG). Materials and Methods: This was a retrospective cohort study 
that included all patients with AF who were treated with NOACs (dabigatran 
or rivaroxaban) in HKL and HSDG. Data were obtained from medical records 
and pharmacy databases. Adherence was assessed using proportion of  days 
covered (PDC) over a 1-year duration. High adherence was defined as PDC 
≥80%. A gap of  >60 days between two consecutive refills was used to define 
non-persistence. Result: There were 281 patients who met the inclusion criteria, 
with 54.1% (n = 152) male. There were 75.1% (n = 211) patients on dabigatran 
and others on rivaroxaban. Only 66.9% (n  =  188) of  patients achieved high 
adherence with PDC ≥80% and 69.8% (n  =  196) were persistence with >60-
day gap over 12 months. Adherence and persistence were both influenced by 
treatment center, whereas polypharmacy only influenced adherence. Conclusion: 
Overall adherence and persistence to NOACs were suboptimal and varied 
between treatment centers, potentially due to institution-specific administrative 
and clinical practice differences. Clinical care and outcomes can potentially be 
optimized by identifying factors affecting adherence and persistence and by 
implementing interventions to improving them.
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O ral anticoagulants (OACs) are used to reduce the risk of stroke and mortality among patients 
with atrial fibrillation (AF) at moderate-to-high 
risk of thrombosis events (CHA₂DS₂-VASc score 
≥2).[1] Non-vitamin K antagonist oral anticoagulants 
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been recently developed and approved as alternatives 
to vitamin K antagonist (VKAs) such as warfarin for 
venous thromboembolism (VTE) and for prevention of 
thrombosis in patients with AF.[2]
AF is a chronic disease that often requires long-
term pharmacotherapy. Medication non-adherence, 
according to various measures, can be as high as 30%–
50% among patients with chronic diseases and is more 
prevalent in patients with asymptomatic diseases such 
as AF and VTE.[3,4] Adherence can be additionally 
challenging for patients with AF as the majority are 
elderly with multiple comorbidities and requiring 
various medications.[5]
NOAC is relatively new within clinical practice in 
Malaysia with limited practice-based data on its use. 
This study aimed to assess the patterns of adherence 




This is an observational retrospective cohort study 
conducted in two tertiary-care referral centers in 
Malaysia: Hospital Kuala Lumpur (HKL) and 
Hospital Serdang (HSDG). These two study sites were 
selected as they have among the highest number of 
NOAC prescriptions compared to other Ministry of 
Health centers in Malaysia. Data were obtained from 
electronic pharmacy dispensing records, treatment-
center databases, and relevant records. Patient-level 
data reflected dispensing from the period between June 
2012 and June 2019. Ethics approval from Medical 
Research Ethical Committee (MREC) was obtained 
with National Medical Research Register (NMRR) 
number (NMRR-17-3020-38667).
Study population
Patients with documented AF diagnosis were included 
if  they fulfilled the following criteria: (1) aged ≥18 years 
on the index date; (2) were prescribed and dispensed 
dabigatran or rivaroxaban; (3) have continuous medical 
and pharmacy records from the index-date until the 
end of study period (i.e., minimum 1 year in order to 
describe 12-month adherence); and (4) first dispensing 
refill reported between 2012 and 2018. The index-date 
was defined as the first date of dispensing of NOACs. 
Dabigatran and rivaroxaban were the selected index-
agents because these are the most commonly prescribed 
NOACs in these treatment centers. Patients with 
defaulted follow-ups were excluded from this study.
Outcomes and study measures
Adherence is defined as “the extent to which a person’s 
behavior (including medication taking) corresponds 
with agreed recommendations from a health care 
provider”[6] and was assessed for patients with AF for at 
least 1 year. Adherence was measured using proportion 
of days covered (PDC), which is the preferred 
method of Pharmacy Quality Alliance (PQA).[7] PDC 
denominator was defined as the number of days from 
the index-date until the end of study period, where 
adherence is measured over 12  months and over 
24 months, whereas the numerator was defined as the 
days of medication covered through the study period 
based on the dispensing refill records. High adherence 
for an individual patient was defined at as PDC ≥80%.[7] 
The sensitivity analysis explored high adherence defined 
as PDC ≥90%.
Persistence is defined as “the interval between the date 
of the first prescription and the point at which an 
unacceptable gap between prescription refills occurs.”[8] 
Treatment non-persistence for NOACs was defined as a 
gap of more than 60 days within a 1-year period.[9] The 
sensitivity analysis explored treatment non-persistence at 
a gap of more than 30 days. Statistical analysis was also 
conducted to identify factors that influenced adherence 
and persistence in the study population, using Statistical 
Package for the Social Sciences (SPSS) software program, 
version 25.0 (IBM Corp. Armonk, NY, USA).
results
There were 281 patients who met the inclusion 
criteria out of  481 patients, who were screened in 
both treatment centers. The majority of  patients were 
above 60  years old, with various comorbidities and 
scored ≥3 on the Charlson Comorbidity Index, had 
high risks of  stroke (CHA₂DS₂-VASc score ≥2) and 
bleeding (HAS-BLED score ≥1) and had no prior 
OACs use. All patients were receiving concomitant 
medication alongside NOACs. Dabigatran was the 
most frequently used NOACs in this study population. 
The baseline characteristics of  the study population 
alongside the findings on adherence and persistence 
are presented in Table 1.
Adherence for PDC ≥80% and PDC ≥90% were 
(66.9%, n  =  188/281) and (55.2%, n  =  155/281), 
respectively, at 12  months. Adherence at 24  months 
improved compared to at 12  months for both PDC 
≥80% (83.0%, n  =  112/135) and PDC ≥90% (68.9%, 
n  =  93/135). Two factors were found to significantly 
influence adherence, which were the treatment center 
at 12  months and polypharmacy (≥5 concurrent 
medications) at 24  months. Persistence for 60- and 
30-day gaps were (69.8%, n  =  196/281) and (58.4%, 
n  =  164/281), respectively, within a 12-month period. 
Treatment center was the only factor that influenced 
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identified factors associated with high adherence and 
persistence are presented in Table 2.
dIscussIon
The main findings in this study are as follows: 
12-month adherence was suboptimal with one-third of 
patients being non-adherent; adherence at 24 months 
improved compared to at 12 months. Adherence was 
influenced by treatment center and polypharmacy. 
Persistence was also suboptimal with one-third of 
patients being non-persistent; and was only influenced 
by treatment center.
Table 1: Baseline characteristics, adherence, and persistence of the study population
Patient Characteristics Study population 
(total=281), n(%)
Adherent population at PDC≥80% 
over 12-months (total=188/281)
Persistent population at 60-days gaps 
over 12-months (total=196/281)
Age(yrs), mean(SD) 67.2(10.0) 67.3(10.0) 67.5(9.9)
Age(yrs)    
 <60 54(19.2) 36/54(66.7%) 36/54(66.7%)
 ≥60 227(80.8) 152/227(67.0%) 160/227(70.5%) 
Sex    
 Male 152(54.1) 106/152(69.7%) 109/152(71.7%)
 Female 129(45.9) 82/129(63.6%) 87/129(67.4%) 
Race    
 Malay 117(41.6) 74/117(63.2%) 80/117(68.4%) 
 Chinese 140(49.8) 101/140(72.1%) 103/140(73.6%) 
 Indian 24(8.5) 13/24(54.2%) 13/24(54.2%)
Treatment-center    
 HSDG 200(71.2) 119/200(59.5%) 126/200(63.0%)
 HKL 81(28.8) 69/81(85.2%)* 70/81(86.4%)*
Charlson comorbidity index 
score, mean (SD)
3.6(1.6) 3.6(1.5) 3.5(1.5)
Charlson comorbidity index 
score
   
 0 5(1.8) 3/5(60.0%) 3/5(60.0%)
 1-2 62(22.1) 42/62(67.7%) 44/62(71.0%)
 3-4 143(50.9) 95/143(66.4%) 101/143(70.6%)
 5-6 61(21.7) 43/61(70.5%) 43/61(70.5%) 
 ≥7 10(3.6) 5/10(50.0%) 5/10(50.0%) 
CHA₂DS₂-VASc score    
 Mean(SD) 3.4(1.5) 3.4(1.5) 3.5(1.5)
 Low(score=0,1) 20(7.1) 15/20(75.0%) 14/20(70.0%)
 High(score=2,3) 141(50.2) 93/141(66.0%) 98/141(69.5%)
 Very-high(score≥4) 120(42.7) 80/120(66.7%) 84/120(70.0%)
HAS-BLED score    
 Mean(SD) 1.65(0.921) 1.63(0.942)  1.64(0.942)
 Low(score=0) 19(6.8) 14/19(73.7%) 14/19(73.7%)
 Medium(score=1-2) 213(75.8) 144/213(67.6%) 149/213(70.0%)
 High(score≥3) 49(17.4) 30/49(61.2%) 33/49(67.3%) 
Index medication    
 Dabigatran 211(75.1) 144/211(68.2%) 151/211(71.6%)






   
 <5 128(45.6) 92/128(71.9%) 97/128(75.8%)*
 ≥5 153(54.4) 96/153(62.7%) 99/153(64.7%) 
Previous use of OACs    
 No 195(69.4) 130/195(66.7%) 135/195(69.2%) 
 Yes 86(30.6) 58/86(67.4%) 61/86(70.9%)
PDC  =  proportion of days covered, SD  =  standard deviation, HKL  =  Hospital Kuala Lumpur, HSDG  =  Hospital Serdang, 
OACs = oral anticoagulants
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Previous studies in various countries have described 
adherence to NOACs by PDC in patients with AF to 
be between 45.2% and 93.6%.[10,11] The findings of this 
study are within this range. Variations of adherence 
to NOACs in patients with AF between studies could 
potentially be related to multiple factors including 
differences between health-care settings, period of 
evaluation, administrative policies, clinical practice, 
interaction between physician and patients, patients’ 
education level and knowledge, medical conditions, 
risk of adverse events, and socioeconomic status of 
the patients.[12,13] Awareness about these predictors 
and efforts to identify relevant factors within a patient 
population and subsequently overcoming them are 
important steps to improve adherence to NOACs 
within an institution.
Adherence over 12 months in our study population was 
66.9% and improved over 24 months to 83.0%. This is in 
contrast to other studies which found NOACs adherence 
to decrease over time between 6 and 24 months.[9,11,14] The 
improved adherence over 24 months in this study could 
potentially be influenced by attrition of less adherent 
patients, either by transfer to other institutions or by 
mortality. However, institutional data was not available 
to explore this further.
Adherence was significantly influenced by two factors: 
treatment center at 12  months and polypharmacy at 
24  months. Higher adherence rate in HKL over the 
first 12  months is potentially due to administrative 
differences between the two institutions. In HKL, there 
is a centralized NOAC clinic with dedicated specialists 
providing clinical care within a structured process of 
care where patients on NOACs receive specialized 
and personalized clinical management alongside 
counselling by pharmacists. In HSDG, only physicians 
from the cardiology department could prescribe 
NOACs but there was no dedicated process of care 
specific to patients on NOACs. It is also possible that 
there were differences in the pharmacy supply stock of 
NOACs between these two institutions, where a stable 
supply would lead to higher adherence as measured by 
PDC, but the retrospective design did not allow further 
exploration of this.
At 24  months, only polypharmacy was found to 
significantly influence adherence, with patients without 
polypharmacy being more likely to be adherent. 
Polypharmacy has been found to be adversely 
associated with medication adherence in various 
studies potentially due to a high likelihood for missing 
doses and increased complexity of pharmacotherapy 
regimens,[15,16] with a majority of studies describing 
polypharmacy as negatively influencing medication 
adherence.[15]
Current evidence has described adherence to be linked 
to health outcomes, with poor adherence to NOACs 
found to be an important predictor for increased 
risk of all-cause mortality and stroke, with hazard 
ratios (HRs) of 1.13 and 1.54, respectively.[5,17] The 
suboptimal adherence in this study indicates that health 
outcomes could potentially be improved in this study 
population by implementing suitable interventions 
and improved clinical care to enhance adherence, 
particularly as the simplicity of NOAC regimens can 
also counterintuitively lead to poor adherence due to 
reduced routine follow-up and its indication for stroke 
prevention in generally asymptomatic patients with 
AF.[18] This is especially so as nearly all of the patients 
in this study had CHA₂DS₂-VASc score of 2 and above, 
which has been found have nearly three times [HR 
2.73] higher risk of stroke compared to patients with 
CHA₂DS₂-VASc scores 0–1.[18]
Persistence in the study population, at 69.8%, was close 
to the upper level found in other studies in patients with 
AF with similar study design and definitions, which 
ranged between 31.6%[9] and 82.8%.[19] Persistence 
over 12  months for both 30- and 60-day gaps was 
only significantly influenced by treatment center with 
persistence observed to be better in HKL compared 
to HSDG. This observation may be due to the same 
factors discussed above that may have influenced 
adherence.
Table 2: Factors associated with high adherence and persistence for the study population
Odds ratio (95%CI) P Value
12-month adherence (PDC ≥ 80%)   
HKL vs. HSDG 3.91(1.99,7.68) <0.0001
24-month adherence (PDC ≥ 80%)   
Concurrent medications <5 vs. ≥5 0.32(0.12,0.89) 0.029
Persistence (60-day gap)   
HKL vs. HSDG 0.26(0.13,0.53) <0.0001
Persistence (30-day gap)   
HKL vs. HSDG 2.42(1.38,4.26) 0.002
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Despite being conducted in two tertiary-care referral 
centers with a catchment population of more than 1 
million people within the Klang Valley, this study 
identified a relatively small number of patients with AF 
on NOACs. This reflected the currently limited use of 
NOACs within Ministry of Health (MoH) tertiary-care 
referral centers, with various administrative prescribing 
restrictions applied which allow only selected 
specialties and consultants to prescribe NOACs to a 
limited number of patients. This restriction on NOACs 
prescribing is likely due to the comparatively high 
acquisition cost of NOACs, which has been estimated 
to be around MYR2945 per patient annually for 
dabigatran and MYR2894 per patient annually for 
rivaroxaban compared to only MYR651 per patient for 
warfarin.[20]
Care must be taken when generalizing the findings 
of this study. These findings were based on the 
availability and accuracy of the electronic pharmacy 
dispensing records, treatment-center databases, and 
relevant records in the study institutions. As measuring 
adherence by PDC reflects the amount of medication 
dispensed over a period of time, a stable pharmacy 
supply would contribute to higher PDC adherence 
rate. It is also possible that some patients could have 
obtained NOACs from community pharmacies 
and primary care clinics, which could potentially 
have influenced adherence. The retrospective design 
did not allow further exploration of these factors 
between the two study institutions. Without national 
health-care databases available across all health-care 
institutions and community pharmacies nationwide, 
conducting a more comprehensive assessment of 
persistence and adherence from secondary resources 
remained challenging. The resource intensive and time-
consuming nature of the data collection process in 
this study pointed to a need to develop large and well-
validated national databases to monitor routine clinical 
care, which could inform improvement of health-care 
service delivery and optimization of health outcomes 
in Malaysia.
conclusIon
Adherence and persistence of patients with AF on 
NOACs in this study population were suboptimal but 
were within the ranges documented in the literature. 
Variations of adherence and persistence between the 
two study institutions indicated that incorporating 
adherence enhancing measures within routine clinical 
care with dedicated specialized services, such as having 
dedicated NOACs clinics with follow-up clinical care 
and pharmacists’ counselling, can have a positive 
impact on adherence and persistence.
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